For more information, view the full Product Monograph at

health-products.canada.ca/dpd-bdpp/

sohonos® palovarotene capsules

IPSEN

MEMBER OF INNOVATIVE MEDICINES CANADA

Understanding the SOHONOS® Educational Program:

A Guide for Prescribers and Pharmacists

Serious Warnings and Precautions

- SOHONOS® is a member of the retinoid class of drugs that is associated with birth defects in humans. SOHONOS® must not be used by patients who are, or intend to become, pregnant due to the risk of teratogenicity. To minimize fetal exposure, SOHONOS® is to be administered only if all conditions for pregnancy prevention are met.
- SOHONOS® has been shown to cause premature physeal closure in growing children with FOP; periodic monitoring (every 3 months) is recommended.

For a comprehensive description of risks associated with SOHONOS®, please refer to the accompanying Product Monograph for further information.

PrSOHONOS® (palovarotene capsules) is indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva.

sohonos® palovarotene capsules

IPSEN

What is SOHONOS® used for?

SOHONOS® (palovarotene capsules) is indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva.

What are the serious risks of SOHONOS®?

- SOHONOS® can cause serious birth defects if taken during pregnancy. Patients must not be pregnant when they start taking SOHONOS® or become pregnant while taking SOHONOS®, or for 1 month after stopping SOHONOS®. SOHONOS® is contraindicated in patients of childbearing potential unless all of the following conditions for pregnancy prevention are met, or they are not at risk for pregnancy (e.g. patient has undergone a hysterectomy, bilateral oophorectomy, bilateral tubal ligation or has been medically confirmed to be postmenopausal).

- Radiological vertebral fractures (spinal fractures) were identified as a risk associated with SOHONOS®.

- SOHONOS® should only be prescribed by physicians knowledgeable in the **SOHONOS® Pregnancy Prevention Plan**.

Patients of Childbearing Potential

- The potential for pregnancy must be assessed for all patients.
- The patient must understand the teratogenic risk and the need to rapidly consult their physician if there is a risk of pregnancy or if they might be pregnant.
- Patients of childbearing potential must use at least one highly effective method of contraception (i.e. IUD) or two effective methods (i.e. combined hormonal contraception in combination with another method of contraception such as a barrier method) during treatment with SOHONOS®.
- The patient must understand and accept to undergo regular pregnancy testing before treatment with SOHONOS®, during treatment and 1 month after stopping treatment.
- The patient must understand and accept the need for effective contraception, without interruption, 1 month before starting treatment, throughout the entire duration of treatment and for 1 month after the end of treatment.
- For those patients taking the flare-up regimen only, patients must continue to use effective contraception even during periods when SOHONOS® is not being taken as the timing of flare-ups may not be predictable.
- The patient acknowledges that they understand the hazards and necessary precautions associated with the use of SOHONOS®.
- The patient is informed and understands the potential consequences of pregnancy and the need to rapidly consult their physician if there is a risk of pregnancy or if they might be pregnant.

These conditions also concern patients of childbearing potential who are not currently sexually active unless the prescriber attests that there are compelling reasons to indicate that there is no risk of pregnancy.

Premature physeal closure (PPC) has been demonstrated to be an important risk associated with SOHONOS® treatment in growing children. In clinical studies, PPC can be irreversible. Potential long-term consequences of PPC include growth arrest, leg length discrepancy, disproportionate growth (epiphyseal growth plate closure preferentially affecting the lower extremities), angular deformity in affected joints, and gait disturbance. Continued monitoring of linear growth and skeletal maturity via X-ray is recommended every 3 months until patients reach skeletal maturity or final adult height (frequency of monitoring may depend on patient characteristics such as age, pubertal status and skeletal maturity).

There are other warnings and precautions associated with taking SOHONOS®. Please read the SOHONOS® Product Monograph.

What is the SOHONOS® Educational Program?

The SOHONOS® Educational Program is a program to educate prescribers, pharmacists, patients, and their caregivers about the serious risks related to SOHONOS®.

Educating Patients about the Risk of Birth Defects Associated with SOHONOS®

SOHONOS® must not be used by patients who are, may be, or intend to become pregnant due to the risk of teratogenicity. SOHONOS® can seriously harm an unborn baby. It can cause serious defects to the unborn baby's brain, face, ears, eyes, heart and certain glands (thymus gland and parathyroid gland). It also makes a miscarriage more likely. This may happen even if SOHONOS® is taken only for a short time during pregnancy. To minimize fetal exposure, SOHONOS® is to be administered only if ALL the conditions described below under **"SOHONOS® Pregnancy Prevention Plan"** are met.

SOHONOS® Pregnancy Prevention Plan

Patients who could get pregnant must meet **ALL** of the conditions below to use SOHONOS®. You might want to use the information below when teaching your patient about the **SOHONOS® Pregnancy Prevention Plan:**

1. Ensure your patient understands they must NOT take SOHONOS® if they are pregnant, or breastfeeding

SOHONOS® can seriously harm an unborn baby. It can cause serious defects to the unborn baby's brain, face, ears, eyes, heart and certain glands (thymus gland and parathyroid gland). It also makes a miscarriage more likely. This may happen even if SOHONOS® is taken only for a short time during pregnancy.

Your patient must NOT

- take SOHONOS® if they are pregnant or if they think they might be pregnant.
- take SOHONOS® if they are breastfeeding. The medicine is likely to pass into their milk and may harm their baby.
- take SOHONOS® if they could get pregnant during treatment.
- get pregnant for one month after stopping this treatment because some medicine may still be left in their body.

SOHONOS® Pregnancy Prevention Plan (*continued*)

2. If your patient could get pregnant, you and your patient must discuss the strict rules to follow before, during and after taking SOHONOS®.

- You must explain the risk of harm to the unborn baby. Your patient must understand why they must not get pregnant and what they need to do to prevent pregnancy.
- You must speak with your patient about contraception and give them information on how to avoid getting pregnant. You may send your patient to a specialist for birth control advice.
- You must speak with your patient about pregnancy testing. Your patient must understand and agree to have regular pregnancy testing.
- You must explain what to do if your patient becomes pregnant, or think they might be pregnant.

3. Your patient must avoid getting pregnant by using effective birth control before, during and after taking SOHONOS®.

- Your patient must be able and willing to comply with the mandatory birth control measures. Discuss with them which methods would be suitable.
- Your patient must use birth control even if they are not sexually active (unless you decide this is not necessary).
- Your patient must use birth control for a month before taking SOHONOS®, during treatment and for a month afterwards.
- Your patient must use at least one highly effective method of birth control (for example, an intrauterine device) or, two effective methods that work in different ways (for example, a hormonal birth control pill and a condom).

If your patient is taking SOHONOS® only to treat flare-ups, they must continue to use effective birth control even during times when they are not taking SOHONOS®. This is because the timing of their flare-ups may not be predictable.

4. Your patient must have pregnancy testing before, during and after taking SOHONOS®

- Before they start treatment, they should take a pregnancy test. The test must show that they are not pregnant when starting treatment with SOHONOS®.
- They must have regular pregnancy tests, every month during treatment with SOHONOS®. You may also ask for your patient to take a pregnancy test 1 month after stopping SOHONOS® because some medicine may still be left in their body.

5. **If your patient becomes pregnant while taking SOHONOS® or within one month after stopping treatment, they must contact you right away**
   - If your patient is still taking SOHONOS®, they must stop treatment and tell you right away.
   - **You and your patient must discuss:**
     - If they want to continue with their pregnancy
     - The serious risk of the baby having severe birth defects
   - You or your patient should report the pregnancy by calling (1-855-215-2288, Option 3). If your patient agrees, you can also enrol them in the SOHONOS® registry by calling the same number (1-855-215-2288, Option 3).

SOHONOS® Pregnancy Prevention Plan



Adapted from the Product Monograph.

*Applies whether your patient is taking SOHONOS® Chronic Treatment or Flare-up Treatment. If your patient is taking SOHONOS® only to treat flare-ups, they must continue to use effective birth control even during times when they are not taking SOHONOS®. This is because the timing of their flare-ups may not be predictable.

Educating Caregivers About the Risk of Premature Physeal Closure (PPC) in Growing Children with Fibrodysplasia Ossificans Progressiva

SOHONOS® should only be prescribed for females ≥8 years and males ≥10 years. There are no clear characteristics that define or predict who will develop PPC, over what period, or after what duration of SOHONOS® exposure.

Prior to initiating SOHONOS® treatment:

All growing children should undergo baseline clinical and radiological assessments including, but not limited to, an assessment of skeletal maturity via hand/wrist and knee X-rays, standard growth curves, and pubertal staging.

Continued monitoring of linear growth and skeletal maturity via X-ray is recommended every 3 months until patients reach skeletal maturity or final adult height (frequency of monitoring may depend on patient characteristics such as age, pubertal status and skeletal maturity). Should evidence of adverse effects on growth and/or PPC be observed, further evaluation and increased monitoring may be required. The decision to temporarily interrupt SOHONOS® during the evaluation period or permanently discontinue treatment should be made based on the individual benefit-risk determination.

Once the patient has reached skeletal maturity or the patient has reached final adult height, no further monitoring for PPC is necessary.

Educating Patients about the Risk of Radiologically Observed Vertebral Fractures

In clinical studies, SOHONOS® has resulted in an increased risk of radiologically observed vertebral (T4 to L4) fractures in treated adult and pediatric patients compared to untreated patients. Whether treatment with SOHONOS® increases the risk of fracture in other regions of the spine or body is not known. Periodic radiological assessment of the spine is recommended.

Ipsen Medical Information

To request Medical Information, report an Adverse Event or Product Quality Complaint for Ipsen Canada's products, please contact Ipsen Canada Medical Information at:
Phone: 1-855-215-2288 (Option 3)
Email: MedInfoandSafetyCanada@Ipsen.com

If you are interested in enrolling a patient in the SOHONOS® registry, please contact Ipsen Biopharmaceuticals Canada Inc. for more information at 1-855-215-2288 (Option 3).

For more information:

Consult the SOHONOS® Product Monograph at: health-products.canada.ca/dpd-bdpp/ for important information relating to adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling Ipsen Medical Information at 1-855-215-2288 (Option 3).

Reference: SOHONOS® Product Monograph. Ipsen Biopharmaceuticals Canada Inc.